enGene Confirms Corporate Name Change to enGene Therapeutics Inc
enGene Therapeutics Inc., a clinical-stage biotechnology company focused on the development of non-viral genetic medicines, has announced that it will officially adopt its new corporate name, “enGene Therapeutics Inc.,” effective April 8, 2026. The company, previously known as enGene Holdings Inc., stated that the name change reflects its strategic evolution as it prepares to transition from a development-stage organization into a potential commercial-stage biopharmaceutical company.
The rebranding marks an important milestone in enGene’s corporate journey, signaling its growing maturity and readiness to bring innovative therapies to market. Central to this transition is the company’s lead investigational therapy, detalimogene voraplasmid, which is currently in advanced clinical development and is being positioned as a potential first-in-class treatment for certain forms of bladder cancer. With a possible regulatory approval anticipated in 2027, the company is aligning its identity to better reflect its future as a fully integrated therapeutic organization.
Ron Cooper, President and Chief Executive Officer of enGene Therapeutics, emphasized the significance of this transition. He noted that the company is entering a critical phase as it prepares for potential commercialization of its lead asset. According to Cooper, the updated corporate name represents not only the company’s progress to date but also its ambition to deliver meaningful treatment options to patients and healthcare providers who are in need of new therapeutic alternatives.
At the heart of enGene’s pipeline is detalimogene voraplasmid, a novel non-viral gene therapy designed to deliver genetic material directly to target cells. Unlike traditional viral-based gene therapies, enGene’s platform utilizes a proprietary delivery system intended to improve safety, tolerability, and repeat dosing potential. This approach is particularly relevant in oncology settings, where localized and controlled gene delivery can offer therapeutic advantages.
The investigational therapy is currently being evaluated in the ongoing LEGEND clinical trial, a multi-cohort study exploring its efficacy and safety across several patient populations with non-muscle invasive bladder cancer. NMIBC is a common form of bladder cancer that remains confined to the inner lining of the bladder but is associated with a high risk of recurrence and progression. Despite existing treatments, many patients experience limited long-term success, highlighting the need for new therapeutic options.
Within the LEGEND trial, particular focus is being placed on a pivotal cohort of patients with BCG-unresponsive NMIBC, including those with carcinoma in situ (CIS). These patients represent a subgroup with especially high unmet medical need, as they do not respond adequately to Bacillus Calmette-Guérin (BCG), the current standard of care. For such patients, treatment options are often limited and may involve invasive procedures such as bladder removal, underscoring the importance of developing effective, bladder-sparing therapies.
Detalimogene voraplasmid is being investigated as a potential alternative that could offer durable responses while preserving bladder function. If successful, the therapy could represent a meaningful advancement in the treatment landscape for NMIBC, providing patients with a less invasive and more targeted approach to disease management.
The company’s decision to adopt the name “enGene Therapeutics Inc.” reflects its intention to emphasize its identity as a therapeutics-focused organization. As it moves closer to potential regulatory approval and commercialization, the company is expected to expand its capabilities in areas such as manufacturing, regulatory affairs, market access, and commercialization infrastructure. The new name aligns with these ambitions, reinforcing its commitment to delivering innovative treatments to patients.
From a financial and operational standpoint, the name change will not impact the company’s publicly traded securities. enGene’s common shares will continue to be listed on the Nasdaq Capital Market under the ticker symbol “ENGN,” while its publicly traded warrants will remain under the symbol “ENGNW.” This continuity ensures that investors and stakeholders can continue to engage with the company without disruption.
The company also confirmed that the corporate name change does not affect the rights of shareholders or warrant holders. No action is required from investors as a result of the transition. However, as part of the administrative update, new identification numbers will be assigned to the company’s securities. The common shares will receive a new CUSIP number of 29286X101 and a new ISIN of CA29286X1015, while the warrants will be assigned a CUSIP number of 29286X119 and an ISIN of CA29286X1197.
Beyond its lead program, enGene continues to advance its broader pipeline of non-viral genetic medicines, leveraging its proprietary delivery platform to explore applications across oncology and potentially other therapeutic areas. The company’s approach aims to overcome some of the limitations associated with traditional gene therapies, particularly in terms of safety and repeat dosing, which could expand the applicability of genetic medicines to a wider range of diseases.
The transition to a commercial-stage organization represents a pivotal moment for enGene, as it shifts from a focus on early-stage research and development to the execution of commercialization strategies. This includes preparing for potential product launches, building relationships with healthcare providers, and ensuring that patients can access new therapies in a timely and efficient manner.
In summary, the adoption of the new corporate name, enGene Therapeutics Inc., reflects the company’s evolution and its readiness to enter the next phase of growth. With a promising lead candidate in detalimogene voraplasmid and an ongoing pivotal clinical program in non-muscle invasive bladder cancer, the company is positioning itself to make a meaningful impact in the field of genetic medicine. As it advances toward potential regulatory approval and commercialization, enGene is focused on delivering innovative solutions that address significant unmet medical needs and improve outcomes for patients worldwide.
About Non-Muscle Invasive Bladder Cancer (NMIBC)
Non-muscle invasive bladder cancer (NMIBC) is a disease that poses a significant burden on both patients and clinics and has a massive economic impact on our healthcare system. NMIBC occurs when cancer cells grow in the tissues that line the interior of the bladder, but the cancer has not yet penetrated the muscle of the bladder wall. NMIBC can present as papillary outgrowths from the bladder wall, which are typically resected, or as carcinoma in situ (CIS), which consists of flat, multifocal lesions that cannot be resected.
The two forms can also co-occur. About 75-80% of new bladder cancer diagnoses are NMIBC. Patients suffering from high-risk NMIBC who are unresponsive to the standard of care, Bacillus Calmette-Guérin (BCG), face high rates of disease recurrence (50-70%) and are potentially subject to full removal of the bladder (cystectomy) as a curative but life-altering next step.
About Detalimogene Voraplasmid
Detalimogene is a novel, investigational, non-viral gene therapy for patients with high-risk, non-muscle invasive bladder cancer (NMIBC), including Bacillus Calmette-Guérin (BCG)-unresponsive disease. It is designed to be instilled in the bladder and elicit a powerful yet localized anti-tumor immune response.
Detalimogene was developed using the Company’s Dually Derivatized Oligochitosan® (DDX) platform, a technology designed to transform how gene therapies are accessed by patients and utilized by clinicians. Medicines developed with the DDX platform can potentially overcome the limitations of viral-based gene therapies, reduce complexities related to safe handling and cold storage, and streamline both manufacturing processes and administration paradigms.
Detalimogene has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) based on its potential to address the high unmet medical need for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC with or without resected papillary tumors who are unable to undergo cystectomy. The RMAT program is intended to expedite the development and review of regenerative medicine therapies for serious or life-threatening conditions, where preliminary clinical evidence suggests potential to address unmet medical needs.
Similarly, Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Detalimogene has also been selected to participate in the FDA’s Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) program. The FDA created the CDRP Program to facilitate CMC development for therapies with compressed clinical development timeframes based on the anticipated clinical benefits of earlier patient access to the therapy.
About the LEGEND Trial
Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEGEND trial to establish its safety and efficacy in high-risk NMIBC. LEGEND’s pivotal cohort (Cohort 1) consists of 125 patients with high-risk, BCG-unresponsive NMIBC with CIS (with or without papillary disease) and is designed to serve as the basis of the Company’s planned Biologics License Application (BLA) filing.
In addition to this pivotal cohort, LEGEND includes three additional cohorts, including NMIBC patients with CIS who are naïve to treatment with BCG (Cohort 2a); NMIBC patients with CIS who have been exposed to BCG but have not received adequate BCG treatment (Cohort 2b); and BCG-unresponsive high-risk NMIBC patients with papillary-only disease (Cohort 3). The LEGEND trial is actively enrolling patients with sites participating in the USA, Canada, Europe, and the Asia-Pacific region.
About enGene
enGene Therapeutics Inc. is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden.
Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. Detalimogene was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA.
Source Link: https://www.businesswire.com/
